Cost-effectiveness of TNF-α inhibition in active ankylosing spondylitis: A systematic appraisal of the literature
Working Group Health Economics in Rheumatology, Clinic for Immunology and Rheumatology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. Expert Review of Pharmacoeconomics & Outcomes Research
(Impact Factor: 1.67).
06/2012; 12(3):307-17. DOI: 10.1586/erp.12.19
Ankylosing spondylitis (AS) is the most frequent prototype of spondyloarthritides. Substantial direct costs and productivity losses often arise in young patients. Currently, tumor necrosis factor (TNF) inhibitors are the only approved therapy escalation when usual care (physiotherapy and NSAIDs) proves to be insufficient. Owing to their high medication costs, TNF inhibitors are a target of cost-effectiveness analyses. There is consistent evidence regarding the use of TNF inhibitors according to recommendations in patients with active AS finding TNF inhibitors to be cost effective from a societal perspective. However, there are relevant uncertainties (discontinuation rate and progression rate) in the long-term estimates of the cost-effectiveness analyses analyzed. Whether TNF inhibitors are cost effective from an insurance perspective in the long run will have to be addressed by models based on observational data.
Available from: Paul Emery
Annals of the Rheumatic Diseases 01/2013; · 10.38 Impact Factor
Available from: Florian M P Meier
[Show abstract] [Hide abstract]
ABSTRACT: Introduction: This study investigated the effectiveness of combining reduced tumor-necrosis-factor alpha inhibitor therapy (TNFi) with physical therapy in active spondyloarthritis and its potential cost effectiveness.
Methods: Patients, which fulfilled the Assessment of SpondyloArthritis International Society (ASAS) criteria for classification of axial spondyloarthritis and presented with a Bath Ankylosing Spondylitis Activity Index (BASDAI) of greater than 4 were considered for this six-month proof-of-concept study. Patients were asked to participate in physical therapy sessions either at the hospital or at cooperating physical therapy practices. Etanercept (ETC) was administered weekly in a reduced dosage of 25mg subcutaneously for six month and was combined with intensive physiotherapy sessions of 30 minutes three times a week for 4 month, followed by an observational period of 2 months without physiotherapy, but continued low-dose ETC therapy.
Results: A significant decrease of BASDAI was observed after 16 weeks of combination therapy (n=20; median 6.0 vs. 3.2; IQR 5.1-6.7, 2.4-4.8 respectively; p<0.0001). No difference was seen after 16 weeks for patients treated at the hospital or at participating physiotherapy practices (median BASDAI 2.95 vs. 3.28; IQR 1.2-4.3, 2.25-6.25 respectively; p=0.1902). A simplified calculation estimated a total saving of the combination therapy compared to full-dose ETC therapy of approximately 76,000€ for all patients during the study period.
Conclusions: The results of the study show that intensive physiotherapy could serve as a substitute for a reduced dosage of TNFi for patients with active spondylarthritis. Therefore, combination therapy of low-dose ETC with physical therapy could be a cost-effective alternative for patients with active spondyloarthritis.
The Journal of Rheumatology 09/2014; 41(9):1897-8. DOI:10.3899/jrheum.131431 · 3.19 Impact Factor
Available from: msj.sagepub.com
[Show abstract] [Hide abstract]
ABSTRACT: Spasticity is an extremely common, distressing and disabling symptom of multiple sclerosis. Limited data suggest the associated health care costs correlate with increasing severity and place a high economic burden on individuals, health care systems and society.
The aim of this study was to quantify the impact of multiple sclerosis spasticity on health care resources and the associated costs at different levels of severity in people with multiple sclerosis in the United Kingdom.
An online survey was carried out to understand the resources used in the management of spasticity in multiple sclerosis. The questionnaire asked health care specialists to estimate their involvement and the resource use associated with different levels of spasticity, and the survey outputs were used to derive the resource costs.
The level and cost of care substantially increased with the degree of spasticity. Key factors contributing to high annual costs per patient were home care, hospital admissions and high-cost items, such as hospital beds.
Based on the survey results, it can be assumed that managing spasticity early and effectively could result in substantial cost savings, in addition to the improvements in health-related quality of life.
© The Author(s), 2015.
Multiple Sclerosis 01/2015; 21(12). DOI:10.1177/1352458514566416 · 4.82 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.